Moderna: Our COVID-19 vaccine protects kids as young as 12

Lawrence, KS – According to the statement, Moderna officials say that they will submit its teen data to the U.S. Food and Drug Administration and other global regulators early next month.

Moderna studied more than 3,700 12- to 17-year-olds.

Preliminary findings showed the vaccine triggered the same signs of immune protection in kids as it does in adults, and the same kind of temporary side effects such as sore arms, headache and fatigue.

Both Pfizer and Moderna have begun testing in even younger children, from age 11 down to 6-month-old babies and experts hope to see some results in the fall.